Japanese-Founded Regulatory T-cell Reprogramming Company RegCell Secures $45.8M in Funding and Completes U.S. Headquarters Transition
- Editor
- Mar 18
- 2 min read
Whats Happening:
RegCell, a biotechnology company developing therapies for autoimmune diseases and transplantation, has secured $45.8 million in funding and completed its transition to a U.S.-based entity. The funding includes an $8.5 million oversubscribed seed round and up to $37.3 million in non-dilutive investment from Japan's Agency for Medical Research and Development (AMED). This move aims to accelerate clinical development, global partnerships, and commercialization opportunities for the company's epigenetic regulatory T-cell reprogramming platform.
Key Moves:
RegCell secures $45.8 million in total funding, including $8.5M seed round and $37.3M from AMED
Company transitions to a U.S.-based entity to accelerate growth and partnerships
Plans to initiate first-in-human clinical trials in 2025 for autoimmune indications
By The Numbers:
$8.5 million raised in oversubscribed seed financing
Up to $37.3 million in non-dilutive funding from AMED
First-in-human trials planned for 2025
Key Quotes:
"This funding accelerates RegCell's mission of developing potentially curative treatments for autoimmune diseases and transplantation and provides a very efficient path to clinical proof of concept." - Professor Shimon Sakaguchi, Scientific Founder
"This financial support and U.S.-based restructuring are not just strategic steps; they are forces that will drive both our clinical development and business success in the years ahead." - Dr. Michael McCullar, CEO of RegCell
Bottom Line:
RegCell's substantial funding and strategic move to the U.S. position the company to accelerate the development of its innovative epigenetic regulatory T-cell reprogramming platform. This transition could potentially lead to breakthrough therapies for autoimmune diseases and transplantation, with clinical trials set to begin in 2025. The support from both private investors and the Japanese government underscores the potential impact of RegCell's technology in addressing unmet medical needs.
Comments